CO2021003608A2 - Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de estos - Google Patents
Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de estosInfo
- Publication number
- CO2021003608A2 CO2021003608A2 CONC2021/0003608A CO2021003608A CO2021003608A2 CO 2021003608 A2 CO2021003608 A2 CO 2021003608A2 CO 2021003608 A CO2021003608 A CO 2021003608A CO 2021003608 A2 CO2021003608 A2 CO 2021003608A2
- Authority
- CO
- Colombia
- Prior art keywords
- epsilon
- fcer1a
- bind
- alpha
- binding molecules
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title abstract 2
- 102000036639 antigens Human genes 0.000 title abstract 2
- 108091007433 antigens Proteins 0.000 title abstract 2
- 206010002198 Anaphylactic reaction Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 210000001744 T-lymphocyte Anatomy 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 230000036783 anaphylactic response Effects 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pulmonology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862721921P | 2018-08-23 | 2018-08-23 | |
| PCT/US2019/047601 WO2020041537A1 (en) | 2018-08-23 | 2019-08-22 | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021003608A2 true CO2021003608A2 (es) | 2021-04-30 |
Family
ID=67876086
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0003608A CO2021003608A2 (es) | 2018-08-23 | 2021-03-19 | Anticuerpos anti-fc épsilon-r1 alfa (fcer1a), moléculas de unión a antígeno biespecíficas que se unen a fcer1a y cd3 y usos de estos |
Country Status (18)
| Country | Link |
|---|---|
| US (2) | US11578127B2 (enExample) |
| EP (1) | EP3840841A1 (enExample) |
| JP (2) | JP7402223B2 (enExample) |
| KR (1) | KR20210049863A (enExample) |
| CN (1) | CN112888482B (enExample) |
| AU (1) | AU2019325565B2 (enExample) |
| BR (1) | BR112021003023A2 (enExample) |
| CA (1) | CA3109513A1 (enExample) |
| CL (2) | CL2021000437A1 (enExample) |
| CO (1) | CO2021003608A2 (enExample) |
| EA (1) | EA202190601A1 (enExample) |
| IL (1) | IL280745A (enExample) |
| MX (1) | MX2021002165A (enExample) |
| MY (1) | MY204368A (enExample) |
| PH (1) | PH12021550322A1 (enExample) |
| SG (1) | SG11202101608XA (enExample) |
| WO (1) | WO2020041537A1 (enExample) |
| ZA (1) | ZA202100919B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3840841A1 (en) | 2018-08-23 | 2021-06-30 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
| WO2021159128A2 (en) * | 2020-01-31 | 2021-08-12 | Randy Leiman Allen | Methods and kit for detection of analytes |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| BRPI0515589A (pt) | 2004-09-02 | 2008-07-29 | Genentech Inc | polipeptìdeos ou anticorpos de ligação de antìgeno isolado, anticorpo isolado, método para regular de forma negativa a atividade de fc(gama)riib, métodos de tratamento, anticorpos biespecìficos isolados, métodos de inibição de uma resposta imune, de supressão na liberação de histamina, de ativação de fc(gama)riib, de inibição da expressão do receptor fc(épsilon)ri, composição e kit |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| SI2975051T1 (sl) | 2009-06-26 | 2021-08-31 | Regeneron Pharmaceuticals, Inc. | Zlahka izolirana bispecifična protitelesa z nativnim imunoglobulinskim formatom |
| DK2505654T4 (da) | 2010-02-08 | 2020-07-27 | Regeneron Pharma | Mus med fælles letkæde |
| WO2012142286A1 (en) * | 2011-04-12 | 2012-10-18 | University Of Cincinnati | Methods for suppressing allergic reactions |
| WO2012169741A2 (ko) | 2011-06-07 | 2012-12-13 | (주)네오팜 | ＦｃεＲＩ 특이적 인간 항체 및 이를 포함하는 알레르기 질환 치료 또는 진단용 조성물 |
| JOP20200236A1 (ar) * | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| EP2837637A1 (en) | 2013-08-16 | 2015-02-18 | SuppreMol GmbH | Novel anti-FcyRIIB IgG-type antibody |
| CN104293738A (zh) | 2013-09-11 | 2015-01-21 | 李莉 | 一种抗人FcεRⅠα亚基单克隆抗体及其应用 |
| EP2982693A1 (en) * | 2014-08-07 | 2016-02-10 | Affimed Therapeutics AG | CD3 binding domain |
| AU2015303142B2 (en) | 2014-08-13 | 2020-08-06 | Suppremol Gmbh | Novel antibodies directed to Fc gamma receptor IIB and Fc epsilon receptor |
| CN104800164B (zh) | 2015-04-13 | 2017-11-07 | 上海市第一人民医院 | 一种雷公藤免疫纳米粒及用途 |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| EP3443006B1 (en) | 2016-04-13 | 2023-08-02 | Sanofi | Trispecific and/or trivalent binding proteins |
| PT3515946T (pt) | 2016-09-23 | 2022-08-04 | Regeneron Pharma | Anticorpos anti-muc16 (mucin 16) |
| EP3840841A1 (en) | 2018-08-23 | 2021-06-30 | Regeneron Pharmaceuticals, Inc. | Anti-fc epsilon-r1 alpha (fcer1a) antibodies, bispecific antigen-binding molecules that bind fcer1a and cd3, and uses thereof |
-
2019
- 2019-08-22 EP EP19765582.2A patent/EP3840841A1/en active Pending
- 2019-08-22 WO PCT/US2019/047601 patent/WO2020041537A1/en not_active Ceased
- 2019-08-22 MX MX2021002165A patent/MX2021002165A/es unknown
- 2019-08-22 US US16/547,910 patent/US11578127B2/en active Active
- 2019-08-22 CN CN201980069380.5A patent/CN112888482B/zh active Active
- 2019-08-22 EA EA202190601A patent/EA202190601A1/ru unknown
- 2019-08-22 MY MYPI2021000853A patent/MY204368A/en unknown
- 2019-08-22 JP JP2021510030A patent/JP7402223B2/ja active Active
- 2019-08-22 AU AU2019325565A patent/AU2019325565B2/en active Active
- 2019-08-22 KR KR1020217008580A patent/KR20210049863A/ko not_active Ceased
- 2019-08-22 BR BR112021003023-9A patent/BR112021003023A2/pt unknown
- 2019-08-22 CA CA3109513A patent/CA3109513A1/en active Pending
- 2019-08-22 SG SG11202101608XA patent/SG11202101608XA/en unknown
-
2021
- 2021-02-09 IL IL280745A patent/IL280745A/en unknown
- 2021-02-10 ZA ZA2021/00919A patent/ZA202100919B/en unknown
- 2021-02-15 PH PH12021550322A patent/PH12021550322A1/en unknown
- 2021-02-19 CL CL2021000437A patent/CL2021000437A1/es unknown
- 2021-03-19 CO CONC2021/0003608A patent/CO2021003608A2/es unknown
-
2023
- 2023-01-12 US US18/153,522 patent/US12441797B2/en active Active
- 2023-02-13 CL CL2023000442A patent/CL2023000442A1/es unknown
- 2023-10-03 JP JP2023172194A patent/JP7541167B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP2023171909A (ja) | 2023-12-05 |
| CN112888482A (zh) | 2021-06-01 |
| ZA202100919B (en) | 2025-10-29 |
| AU2019325565B2 (en) | 2025-09-04 |
| US20230331845A1 (en) | 2023-10-19 |
| WO2020041537A1 (en) | 2020-02-27 |
| BR112021003023A2 (pt) | 2021-05-11 |
| US11578127B2 (en) | 2023-02-14 |
| US12441797B2 (en) | 2025-10-14 |
| US20200062844A1 (en) | 2020-02-27 |
| CL2021000437A1 (es) | 2021-09-03 |
| CL2023000442A1 (es) | 2023-11-24 |
| WO2020041537A8 (en) | 2020-09-10 |
| NZ772900A (en) | 2025-05-02 |
| JP2021533806A (ja) | 2021-12-09 |
| SG11202101608XA (en) | 2021-03-30 |
| CN112888482B (zh) | 2024-06-25 |
| CA3109513A1 (en) | 2020-02-27 |
| IL280745A (en) | 2021-04-29 |
| EA202190601A1 (ru) | 2021-07-14 |
| MX2021002165A (es) | 2021-07-16 |
| PH12021550322A1 (en) | 2021-10-04 |
| AU2019325565A1 (en) | 2021-03-11 |
| JP7402223B2 (ja) | 2023-12-20 |
| KR20210049863A (ko) | 2021-05-06 |
| JP7541167B2 (ja) | 2024-08-27 |
| MY204368A (en) | 2024-08-26 |
| EP3840841A1 (en) | 2021-06-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021000131A1 (es) | Anticuerpos anti-bcma x anti-cd3 biespecíficos y usos de estos. | |
| CL2023000442A1 (es) | Anticuerpos y fragmentos de unión a antígeno específicos para fcer1a, y sus usos | |
| CL2021001573A1 (es) | Anticuerpos anti-muc16 x anti-cd28 biespecíficos y usos de estos. | |
| CO2019000372A2 (es) | Anticuerpos contra proteína 3 que contiene el dominio de mucina e inmunoglobulina de linfocitos t (tim3) y sus usos | |
| MX2021007290A (es) | Anticuerpo humanizado anti-pd-1 humana. | |
| CL2019000738A1 (es) | Anticuerpos anti-steap2, conjugados anticuerpo-fármaco, y moléculas de fijación al antígeno biespecíficas que se fijan a steap2 y cd3, y usos de estos. | |
| CL2020002305A1 (es) | Uso de anticuerpos sirpa v1 antihumanos y procedimiento de producción de anticuerpos anti-sirpa v1 | |
| MX2019003326A (es) | Anticuerpos anti-muc16-cd3 biespecificos y conjugados anti-muc16-farmaco. | |
| NI202000051A (es) | Anticuerpos monoclonales y métodos para utilizar los mismos. | |
| CO2017006989A2 (es) | Anticuerpos contra el inmunorreceptor de células t con dominios de inmunoglobulina y de porción inhibidora con base en tirosina del inmunorreceptor (tigit) | |
| UY35042A (es) | Anticuerpos anti-cd3, moléculas de unión a antígeno biespecíficas que se unen a cd3 y cd20, y usos de los mismos. | |
| CO2021009689A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso. | |
| CO2020014343A2 (es) | Anticuerpos específicos para cd3 y sus usos | |
| CO2021008204A2 (es) | Anticuerpos monoclonales que se unen específicamente a la región beta de la familia trbv-9 del receptor de células t humano, y los métodos para su uso | |
| ECSP22015044A (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| CO2018004569A2 (es) | Anticuerpos que se unen al receptor cannabinoide 1 (cb1) humano | |
| DOP2024000117A (es) | Anticuerpos anti-c3 y fragmentos de unión al antígeno de estos y sus usos para tratar enfermedades oftálmicas u oculares | |
| UY37914A (es) | Anticuerpo monoclonal contr il-5r | |
| MX2025010218A (es) | Anticuerpos multiespecificos anti-cldn6 y anti-cd3 y metodos de uso | |
| CO2025013101A2 (es) | Anticuerpos multiespecíficos anti–cd3 y métodos de uso | |
| AR119536A1 (es) | Anticuerpos anti-ms4a4a y métodos de uso de los mismos | |
| AR120991A1 (es) | Anticuerpos anti-ccr8 y sus usos | |
| AR116616A1 (es) | Variantes de anticuerpo anti-lap y usos de las mismas |